IPXL, HLF And AZN, Pushing Drugs Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 29 points (0.2%) at 17,012 as of Tuesday, July 29, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,550 issues advancing vs. 1,408 declining with 169 unchanged.

The Drugs industry currently sits up 1.0% versus the S&P 500, which is up 0.1%. Top gainers within the industry include Pharmacyclics ( PCYC), up 11.9%, United Therapeutics ( UTHR), up 7.5%, Regeneron Pharmaceuticals ( REGN), up 1.2%, Sanofi ( SNY), up 1.0% and Novo Nordisk A/S ( NVO), up 0.8%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Impax Laboratories ( IPXL) is one of the companies pushing the Drugs industry lower today. As of noon trading, Impax Laboratories is down $4.21 (-15.0%) to $23.82 on heavy volume. Thus far, 2.3 million shares of Impax Laboratories exchanged hands as compared to its average daily volume of 618,200 shares. The stock has ranged in price between $23.26-$24.11 after having opened the day at $23.43 as compared to the previous trading day's close of $28.03.

Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products; and develops and markets branded products. The company operates through two segments, Global Pharmaceuticals Division and Impax Pharmaceutical Division. Impax Laboratories has a market cap of $2.0 billion and is part of the health care sector. Shares are up 11.5% year-to-date as of the close of trading on Monday. Currently there is 1 analyst that rates Impax Laboratories a buy, 2 analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Impax Laboratories as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Impax Laboratories Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Herbalife ( HLF) is down $7.52 (-11.1%) to $59.96 on heavy volume. Thus far, 6.4 million shares of Herbalife exchanged hands as compared to its average daily volume of 2.0 million shares. The stock has ranged in price between $59.10-$61.96 after having opened the day at $59.42 as compared to the previous trading day's close of $67.48.

Herbalife Ltd., a nutrition company, sells weight management, healthy meals and snacks, sports and fitness, energy and targeted nutritional products, and personal care products worldwide. Herbalife has a market cap of $6.5 billion and is part of the consumer goods sector. Shares are down 14.3% year-to-date as of the close of trading on Monday. Currently there are 4 analysts that rate Herbalife a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Herbalife as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, good cash flow from operations, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Herbalife Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, AstraZeneca ( AZN) is down $0.37 (-0.5%) to $73.52 on average volume. Thus far, 2.7 million shares of AstraZeneca exchanged hands as compared to its average daily volume of 5.1 million shares. The stock has ranged in price between $73.14-$73.54 after having opened the day at $73.49 as compared to the previous trading day's close of $73.89.

AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. AstraZeneca has a market cap of $94.0 billion and is part of the health care sector. Shares are up 24.5% year-to-date as of the close of trading on Monday. Currently there is 1 analyst that rates AstraZeneca a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates AstraZeneca as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full AstraZeneca Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Starbucks Surprises With U.S. Sales Up 2%

Starbucks Surprises With U.S. Sales Up 2%

Dow Jumps 238 Points as S&P 500, Nasdaq Also Climb

Dow Jumps 238 Points as S&P 500, Nasdaq Also Climb

Why Nashville, Denver, LA Should Reconsider Bids for Amazon HQ2

Why Nashville, Denver, LA Should Reconsider Bids for Amazon HQ2

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

Jim Cramer: Visa Is a Technology Company That Masquerades as a Financial Company

Jim Cramer: Visa Is a Technology Company That Masquerades as a Financial Company